Share this article
First-line indication offers Canadians with advanced lung cancer new treatment options
TORONTO, March 17, 2021 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has issued ALUNBRIG
® (brigatinib tablets) marketing authorization without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).
1 The approval is based on results from the phase 3 ALTA-1L trial which evaluated 275 patients and showed that once-daily ALUNBRIG
® was superior to crizotinib on measures of efficacy and tolerability making it a promising first-line treatment option.
One Billion People to Receive COVID-19 Communication Powered by Twilio Within 12-24 Months
By
Staff
4 days ago
$11 million in new grants and product credits for initiatives supporting equitable access and education to at-risk and under-served communities
Over 450 Federal, State and Local Governments, Health Services, Educational Institutions, NGOs and Nonprofits rely on Twilio for COVID-19 communication
Twilio has seen usage in over 180 countries, representing 97% of the global population for COVID-19 response initiatives
SAN FRANCISCO–(BUSINESS WIRE)–Twilio (NYSE: TWLO), the leading cloud communications platform, today announced that one billion people will receive COVID-19 communication powered by Twilio within the next 12-24 months to support an accelerated and equitable rollout of the COVID-19 vaccine. Twilio will help its customers streamline communication, distribution, coordination and administration through its customer engagement platform, Twilio funding and oth
is a valuable tool for health care providers to help prescribe the right drug for the right patient to enhance efficacy and avoid side effects.
A new research paper funded in part by the National Heart, Lung and Blood Institute (NHLBI) shows a clear advantage of genetic testing in helping health care providers choose the appropriate anti-platelet drug. Testing helps determine if a patient carries genetic variants in CYP2C19 that cause loss of its function. These variants interfere with the body’s ability to metabolize and activate clopidogrel, an anti-platelet medication.
Anti-platelet drugs are given to prevent complications from blood clotting after a procedure to open clogged arteries. These patients can use one of the various anti-platelet medications, such as clopidogrel, ticagrelor or prasugrel.
I knew it wouldn t be easy to score a COVID-19 vaccination.
Besides falling into the 1A group in Pennsylvania, I had reported and written stories about the virus, the vaccinations, the victims and all the emotions around those. There were so many people who desperately needed the shot, so I waited a few weeks to start staking out pharmacies.
For those who have been trying, this is a familiar story. I tried every major store and pharmacy and lots of mom-and-pop pharmacies. I got nowhere.
Some people suggested a window of time that was ideal to search for an appointment. At first, I heard 10 a.m. to 1 p.m., then I ve talked to people who found spots very early in the morning (5 a.m.) or late, late at night (midnight).
Apr 15, 2021
Launched last week, the clinic is being operated by the University Health Network (UHN), with significant participation by Sinai Health and U of T. It operates by appointment only and follows the vaccine priority schedule and ethical guidelines established by the province.
A senior manager at Sinai Health and PhD candidate at U of T’s Institute of Health Policy, Management and Evaluation at the Dalla Lana School of Public Health, Saha says the mood at the clinic is much more upbeat compared to last year’s assessment centre.
“In those early days we didn’t know too much about COVID-19 and how it spread,” Saha said. “There was high anxiety and a lot of nerves. Now that we’re vaccinating against a disease we learned about just over a year ago, the atmosphere is so much brighter.”